Diagnostics Pipeline: Cizzle Bio Introduces Test for Earlier Lung Cancer Detection
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
The CIZ1B biomarker blood-based assay has 95% sensitivity for detecting earliest stage of the cancer
From – Diagnostic Testing & Emerging Technologies
The US Preventive Services Task Force (USPSTF) issued updated recommendations for BRCA-related cancer risk assessment…